


Product Name : HQL-79
Cat. No. : PC-49639
CAS No. : 162641-16-9
Molecular Formula : C₂₂H₂₇N₅O
Molecular Weight : 377.48
Target : PGE synthase
Solubility : 10 mM in DMSO



Biological Activity

HQL-79 (HQL79) is an orally selective inhibitor of human hematopoietic prostaglandin D synthase (**H-PGDS**), inhibits human H-PGDS competitively against the substrate PGH₂ and non-competitively against GSH with K_i of 5 and 3 μM, respectively.

HQL-79 binds to H-PGDS with an affinity that is 12-fold higher in the presence of GSH and Mg²⁺ (K_d, 0.8 μM) than in their absence.

HQL-79 selectively inhibited PGD₂ production by H-PGDS-expressing human megakaryocytes and rat mastocytoma cells with an IC₅₀ value of about 100 μM but only marginally affected the production of other prostanoids.

Orally administered HQL-79 (30 mg/kg body weight) inhibited antigen-induced production of PGD₂, without affecting the production of PGE₂ and PGF₂α, and ameliorated airway inflammation in wild-type and human H-PGDS-overexpressing mice.

References

Aritake K, et al. *J Biol Chem*. 2006 Jun 2;281(22):15277-86.

Tajima T, et al. *J Pharmacol Exp Ther*. 2008 Aug;326(2):493-501.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com